(Q37960820)

26 August 2017

title

How to manage high-risk acute myeloid leukemia (English)

1 reference

26 August 2017

1 reference

E H Estey

1

1 reference

26 August 2017

publication date

25 November 2011

1 reference

26 August 2017

1 reference

26 August 2017

volume

26

1 reference

26 August 2017

issue

5

1 reference

26 August 2017

page(s)

861-869

1 reference

Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

Impacts of pretransplant comorbidities on allogeneic hematopoietic cell transplantation (HCT) outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

Comorbidities and hematopoietic cell transplantation outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

Age and acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

Relapse and death during first remission in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

Anthracycline dose intensification in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

High-dose daunorubicin in older patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

Cytarabine dose for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Par

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

Incorporating hematopoietic cell transplantation (HCT) into the management of adults aged under 60 years with acute myeloid leukemia (AML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

High-resolution typing for unrelated donor transplantation: how far do we go?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

Should double cord blood transplants be the preferred choice when a sibling donor is unavailable?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

Reduced-intensity conditioning transplantation in myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

Reduced mortality after allogeneic hematopoietic-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

Leukemia stem cells and microenvironment: biology and therapeutic targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

The effect of chemotherapy on acute leukemia in the human

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

7 January 2021

Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

7 January 2021

Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

7 January 2021

A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

7 January 2021

The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

7 January 2021

Prognostic index for adult patients with acute myeloid leukemia in first relapse

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

7 January 2021

Monitoring of minimal residual disease in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

7 January 2021

Commentary: Mendelian randomization--an update on its use to evaluate allogeneic stem cell transplantation in leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

7 January 2021

Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

7 January 2021

Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.317

7 January 2021

Identifiers

DOI

10.1038/LEU.2011.317

1 reference

26 August 2017

1 reference